Literature DB >> 16570913

Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.

Weiming Luo1, Qian-Sheng Yu, Santosh S Kulkarni, Damon A Parrish, Harold W Holloway, David Tweedie, Avigdor Shafferman, Debomoy K Lahiri, Arnold Brossi, Nigel H Greig.   

Abstract

A new enantiomeric synthesis utilizing classical resolution provided two novel series of optically active inhibitors of cholinesterase: (-)- and (+)-O-carbamoyl phenols of tetrahydrofurobenzofuran and methanobenzodioxepine. An additional two series of (-)- and (+)-O-carbamoyl phenols of pyrroloindole and furoindole were obtained by known procedures, and their anticholinesterase actions were similarly quantified against freshly prepared human acetyl- (AChE) and butyrylcholinesterase (BChE). Both enantiomeric forms of each series demonstrated potent cholinesterase inhibitory activity (with IC(50) values as low as 10 nM for AChE and 3 nM for BChE), with the exception of the (+)-O-carbamoyl phenols of pyrroloindole, which lacked activity (IC(50) values >1 microM). Based on the biological data of these four series, a structure-activity relationship (SAR) analysis was provided by molecular volume calculations. In addition, a probable transition-state model was established according to the known X-ray structure of a transition-state complex of Torpedo californica AChE-m-(N,N,N-trimethylammonio)-2,2,2-trifluoroacetophenone (TcAChE-TMTFA). This model proved valuable in explaining the enantioselectivity and enzyme subtype selectivity of each series. These carbamates are more potent than, or similarly potent to, anticholinesterases in current clinical use, providing not only inhibitors of potential clinical relevance but also pharmacological tools to define drug-enzyme binding interactions within an enzyme crucial in the maintenance of cognition and numerous systemic physiological functions in health, aging, and disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570913      PMCID: PMC2610450          DOI: 10.1021/jm050578p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

1.  Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.

Authors:  Oscar L Lopez; James T Becker; Judith Saxton; Robert A Sweet; William Klunk; Steven T DeKosky
Journal:  J Am Geriatr Soc       Date:  2005-01       Impact factor: 5.562

2.  Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

Authors:  Mamoru Hashimoto; Hiroaki Kazui; Keiji Matsumoto; Yoko Nakano; Minoru Yasuda; Etsuro Mori
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

3.  Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.

Authors:  Weiming Luo; Qian-sheng Yu; Ming Zhan; Damon Parrish; Jeffrey R Deschamps; Santosh S Kulkarni; Harold W Holloway; George M Alley; Debomoy K Lahiri; Arnold Brossi; Nigel H Greig
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

Review 4.  Cholinesterase inhibitors: A new class of psychotropic compounds.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

5.  In situ selection of lead compounds by click chemistry: target-guided optimization of acetylcholinesterase inhibitors.

Authors:  Antoni Krasiński; Zoran Radić; Roman Manetsch; Jessica Raushel; Palmer Taylor; K Barry Sharpless; Hartmuth C Kolb
Journal:  J Am Chem Soc       Date:  2005-05-11       Impact factor: 15.419

6.  Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging.

Authors:  Florian Nachon; Oluwatoyin A Asojo; Gloria E O Borgstahl; Patrick Masson; Oksana Lockridge
Journal:  Biochemistry       Date:  2005-02-01       Impact factor: 3.162

Review 7.  A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?

Authors:  Paul T Francis; Agneta Nordberg; Steven E Arnold
Journal:  Trends Pharmacol Sci       Date:  2005-02       Impact factor: 14.819

8.  Syntheses of tetrahydrofurobenzofurans and dihydromethanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and ring expansion under reductive conditions on treatment with hydrides.

Authors:  Weiming Luo; Qian-Sheng Yu; Harold W Holloway; Damon Parrish; Nigel H Greig; Arnold Brossi
Journal:  J Org Chem       Date:  2005-08-05       Impact factor: 4.354

Review 9.  An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Authors:  Nigel H Greig; Kumar Sambamurti; Qian-sheng Yu; Arnold Brossi; Gosse B Bruinsma; Debomoy K Lahiri
Journal:  Curr Alzheimer Res       Date:  2005-07       Impact factor: 3.498

Review 10.  Acetylcholinesterase interaction with Alzheimer amyloid beta.

Authors:  Nibaldo C Inestrosa; Juan Paulo Sagal; Marcela Colombres
Journal:  Subcell Biochem       Date:  2005
View more
  14 in total

1.  Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors.

Authors:  Pran Kishore Deb; Anuradha Sharma; Poonam Piplani; Raghuram Rao Akkinepally
Journal:  Mol Divers       Date:  2012-09-21       Impact factor: 2.943

2.  Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.

Authors:  Sugunadevi Sakkiah; Keun Woo Lee
Journal:  Acta Pharmacol Sin       Date:  2012-06-11       Impact factor: 6.150

Review 3.  Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation.

Authors:  Mohammad A Kamal; Shubha Priyamvada; Arivarasu N Anbazhagan; Nasimudeen R Jabir; Shams Tabrez; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2014-03       Impact factor: 4.388

4.  Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.

Authors:  Mohammad A Kamal; Peter Klein; Weiming Luo; Yazhou Li; Harold W Holloway; David Tweedie; Nigel H Greig
Journal:  Neurochem Res       Date:  2007-11-06       Impact factor: 3.996

5.  Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.

Authors:  Mohammad A Kamal; Xianqin Qu; Qian-Sheng Yu; David Tweedie; Harold W Holloway; Yazhou Li; Yi Tan; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2008-01-31       Impact factor: 3.575

6.  Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergic action.

Authors:  Qian-Sheng Yu; Marcella Reale; Mohammad A Kamal; Harold W Holloway; Weiming Luo; Kumar Sambamurti; Balmiki Ray; Debomoy K Lahiri; Jack T Rogers; Nigel H Greig
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2013

7.  Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.

Authors:  Debomoy K Lahiri; George M Alley; David Tweedie; Demao Chen; Nigel H Greig
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

8.  Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability.

Authors:  Federica Vacondio; Claudia Silva; Alessio Lodola; Alessandro Fioni; Silvia Rivara; Andrea Duranti; Andrea Tontini; Silvano Sanchini; Jason R Clapper; Daniele Piomelli; Marco Mor; Giorgio Tarzia
Journal:  ChemMedChem       Date:  2009-09       Impact factor: 3.466

9.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  Exploring different virtual screening strategies for acetylcholinesterase inhibitors.

Authors:  Nibha Mishra; Arijit Basu
Journal:  Biomed Res Int       Date:  2013-11-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.